Previous 10 | Next 10 |
Ocugen press release ( NASDAQ: OCGN ): Q2 GAAP EPS of -$0.09 misses by $0.01 . The Company’s cash, cash equivalents, and restricted cash totaled $115.0 million as of June 30, 2022, compared to $95.1 million as of December 31, 2021. The Company believes that its ...
Dosing patients in U.S. Phase 2/3 COVAXIN ™ (BBV152) clinical trial Completed dosing of patients in Cohort 1 of OCU400 gene therapy product candidate Expanding product pipeline with the regenerative medicine cell therapy program NeoCart ® ...
Ocugen ( NASDAQ: OCGN ) is scheduled to announce Q2 earnings results on Friday, August 5th, before market open. The consensus EPS Estimate is -$0.08 (+38.5% Y/Y) Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates ha...
MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and gene therapies and vaccines, today announced that it will host ...
Today, we take our first look at a small-cap biotech firm called Ocugen. The company has several early-stage gene therapies and is also trying to become a late entrant into the Covid19 vaccine market. An investment analysis follows in the paragraphs below. The best r...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
The back half of 2022 is already shaping up to be a stock picker's market. Today's mixed trading session in the volatile healthcare sector is a case in point. For example, shares of the clinical-stage biotech Ocugen (NASDAQ: OCGN) were down by a hefty 9.5% and Sorrento Therape...
Ocugen (NASDAQ: OCGN) stock was up by more than 7.5% as of 10:30 a.m. ET Wednesday after the government of India announced that it would distribute free booster doses of the Covaxin COVID-19 vaccine to all adults who want them for 75 days starting on Friday. Ocugen itself didn't...
Shares of Ocugen (NASDAQ: OCGN) trended upward on Friday, growing by more than 13.1% as of 4:09 p.m. on news that regulators in India from the National Technical Advisory Group on Immunization's (NTAGI) Standing Technical Sub-Committee (STSC) had opted to recommend the coronavirus v...
With the U.S. FDA saying that COVID-19 booster vaccines need to include protection against Omicron variant subvariants , Ocugen ( NASDAQ: OCGN ) could see its fortunes improved. In January, Ocugen and partner Bharat Biotech reported data on a booster dose of its Covaxi...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to ...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...